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A B S T R A C T
Purpose: Valproate-induced hyperammonemia (VHA) and hyperammonemic encephalopathy (VHE) are
well-known complications of valproate (VPA) treatment. Currently recognised risk factors for VHE
include a high VPA dosage, the need for polytherapy and long duration of treatment. Despite the severe
nature of the epilepsy, presence of concomitant psychiatric manifestations, and frequent need for poly-
pharmacy associated with juvenile ceroid lipofuscinosis (JNCL, Batten disease) neither this disorder nor
other subtypes of neuronal ceroid lipofuscinosis have previously been identiﬁed as risk factors for VHA/
VHE. The aim of the present publication is to describe four cases with VHE in a well-deﬁned Danish
population of JNCL.
Method: An examination of medical records of all 35 patients with JNCL in Denmark was conducted and
revealed fourteen patients treated with VPA.
Results: Four patients treated with VPA developed VHE. All patients were prescribed VPA in standard
dosages, had normal plasma concentrations of VPA and received antiepileptic drug (AED) polytherapy.
Symptoms occurred shortly after commencement or increase in dose of VPA, and were quickly reversible
upon discontinuation of VPA. Carnitine supplement was administrated in two patients, which resulted in
resolution of symptoms and normalized ammonium levels.
Conclusion: Patients with JNCL are in great risk of developing VHA and VHE due to a high rate of
polytherapy. Furthermore, studies have shown that carnitine level can be depressed in JNCL, which may
increase the risk of VHA and VHE. We recommend that increased attention should be given to these
patients.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Valproate (VPA) is a broad spectrum antiepileptic drug which,
besides its use in epilepsy, also is used in treatment of psychiatric
disorders and in migraine prophylaxis. VPA is commonly well-
tolerated when serum-levels are maintained within the therapeu-
tic range, but adverse effects like weight-gain, tremor, sedation,
thrombocytopenia, and leucopenia may occur.1 Serious side effects
include teratogenicity, hepatotoxicity, pancreatitis, bone marrow
suppression, polycystic ovary syndrome, and VPA-induced hyper-
ammonemic encephalopathy (VHE).1 VHE has been reported in
both children and adults, and may untreated lead to life
threatening coma and death. However VPA may also cause
asymptomatic hyperammonemia (VHA).2,3* Corresponding author. Tel.: +45 78451418.
E-mail address: john.oestergaard@skejby.rm.dk (J.R. Østergaard).
http://dx.doi.org/10.1016/j.seizure.2014.02.011
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reNeuronal ceroid lipofuscinoses (NCL) are a group of genetic
diseases characterized by storage and accumulation of ceroid
lipofuscin in the lysosomas and accompanying degeneration of
especially the neuronal cells. The symptoms include retinopathy,
epilepsy, psychiatric problems, dementia and motor dysfunction.
At least ten different disorders are known.4 Juvenile neuronal
ceroid lipofuscinosis (JNCL), also known as Batten disease, is one of
the most common types and is caused by a mutation in the CLN3
gene on chromosome 16.5 In JNCL, loss of vision begins about the
age of ﬁve to six years. Simultaneously, mental deterioration starts
and, as well, a progressive loss of motor functions. Epilepsy
normally initiates at the age of ten years and increases in frequency
and severity with age. Furthermore, social, behavioral and
attention problems emerge. Some patients develop regular
psychosis. The disease usually leads to early death at a mean
age of 22–28 years.6 Major clinical symptoms are listed in Table 1.
Historically, diagnosis required characterization of storage
material by electron microscopy of rectal, conjunctival or skin
biopsies, electro-retinograms showing retinopathy andserved.
Table 1
Major clinical symptoms of JNCL.4
 Visual impairment
 Regression of motor milestones
 Seizures
 Cognitive decline
 Dyspraxia
 Bradykinesi
 Hallucinations
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techniques applied to DNA samples from blood or a buccal swab
will allow the clinicians to make an accurate diagnosis. In
addition, genetic tests are useful for prenatal diagnosis and
genetic counseling of JNCL.4
A Finnish study reported that 70% of patients with JNCL had a
satisfactory seizure control when treated with VPA.6 However,
patients with an unsatisfactory seizure control often need poly-
therapy in order to prevent life threatening seizures,6 which
increases the risk of side effects, including VHA and VHE.2,3,7–22
Despite the severe nature of the epilepsy, occurrence of concomitant
psychiatric manifestations, and need for polypharmacy, occurrence
of VHA/VHE in Batten disease or other subtypes of NCL have not
previously been reported in the literature. The aim of the present
publication is to describe four cases with VHE in a well-deﬁned
Danish population of Batten patients and to provide a review of VHE.
2. Methods
In Denmark all patients with JNCL are associated to the Centre
for Rare Diseases, Department of Pediatrics, Aarhus University
Hospital. In March 2012 a thorough examination of medical
records of all 35 patients with JNCL was conducted.5 The records
contain a continuously maintained history of the clinical course,
including seizure activity, medication used and hospital admis-
sions. Fourteen patients received VPA. Consecutive measurements
of ammonium during VPA treatment were at that time not part of
the routine. However, four cases with suspected VHE were
revealed. None of these four patients had any underlying metabolic
disease besides their JNCL. All were homozygous for the common
1.02 kb deletion in the CLN3 gene.5 Normal range of ammonium is
11–32 mmol/l and VPA 300–700 mmol/l. In addition, a literature
search using the Pubmed database was conducted using the
following terms: valproate, encephalopathy, hyperammonemia,
valproate-induced hyperammonemic encephalopathy, Batten dis-
ease, juvenile ceroid lipofuscinosis. Publications without reports of
VPA and ammonium levels were excluded.
3. Case reports
3.1. Case 1
Case 1, a 19-year old male was admitted to the acute medical unit
due to increasing drowsiness, which had emerged close to coma. He
was diagnosed with JNCL at the age of six. Three weeks prior to the
admission, VPA (1000 mg/24 h; 13 mg/kg/24 h) was initiated. He
still received oxcarbazepine (1500 mg/24 h) and quetiapin (200 mg/
24 h). On admission, which was shortly after intake of VPA, plasma
level of VPA was 756 mmol/l. As the symptoms occurred shortly after
introduction of VPA, VHE was suspected. Accordingly, VPA was
discontinued and ammonium level and liver parameters were
measured. There was no impact on the liver parameters. Ammonium
level was 110 mmol/l. Within 24 h after discontinuation of VPA he
started to wake up, and after 48 h he had completely regained
consciousness. The ammonium level was reduced to 48 mol/l.3.2. Case 2
Case 2, a 17-year old female diagnosed with JNCL at the age of
seven. She had showed a rapid progression and suffered severe
epilepsy. In addition to phenobarbital (90 mg/24 h) and clonaze-
pam (7 mg/24 h), VPA (300 mg/24 h; 6 mg/kg/24 h) was pre-
scribed. Six weeks later she experienced increased drowsiness,
but with rather unaffected consciousness. VPA level was
261 mmol/l, and ammonium level was 83 mmol/l. There was no
impact on liver parameters. One week later, the ammonium level
had increased to 132 mmol/l, and as she now was drowsy all the
day, VPA was discontinued. Within the next two days, she
gradually resolved to her habitual status, and one week later,
the ammonium level was within the normal range, i.e. below
32 mmol/l.
3.3. Case 3
Case 3, a 22-year old female admitted to hospital due to
increasing drowsiness. JNCL was diagnosed at the age of six years.
Epilepsy initiated when she was 12 years old. Initially, the epilepsy
was well controlled by clobazam (60 mg/24 h; 1 mg/kg/24 h), but
due to an increase in seizure activity, VPA was added. Four months
prior to admission, the dose was increased to 1600 mg/kg/24 h
(26 mg/kg/24 h). At admission, the levels of VPA and ammonium
were 596 mmol/l and 58 mmol/l, respectively. Liver parameters
were normal. The VPA therapy was continued unchanged, and
administration of carnitine 250 mg/day was initiated. Soon after,
her drowsiness resolved, and the level of ammonium gradually
decreased to 9 mmol/l.
3.4. Case 4
Case 4, an 18-year old female diagnosed with JNCL at the age of
eight years. Initially, she was treated with a combination of
topiramate (TPM) (350 mg/kg/24 h) and oxcarbazepine (2100 mg/
kg/24 h). Due to increase in seizure frequency, VPA (1000 mg/24 h;
16 mg/kg/24 h) was initiated eight months earlier, and at
admission she had been seizure free for several months. However,
a severe drowsiness close to lethargy had gradually emerged
despite low plasma levels of VPA (267 mmol/l). VHE was suspected
and she was admitted to hospital. Ammonium level was however
only slightly increased (63 mmol/l). Liver parameters and carnitine
levels were within normal range (free carnitine: 39 mmol/l (24–
64 mmol/l); acetylcarnitine: 3.55 mmol/l (1–13.62 mmol/l)). De-
spite normal ranges of carnitive levels, administration of carnitine
250 mg was initiated. In addition, VPA dose was reduced to
500 mg/24 h. Subsequently, the level of ammonium decreased to
38 mmol/l, and drowsiness resolved. Few weeks later, seizures
again increased in frequency and severity, and the dose of VPA was
gradually increased to 1500 mg/24 h (25 mg/kg/24 h) under the
guise of carnitine treatment. She then became lethargic. The
plasma concentration of VPA and ammonium level had increased
to 495 mmol/l and 61 mmol/l, respectively. The dose of carnitine
was increased to 500 mg/24 h, and within few days, despite an
unchanged VPA dose, the lethargy disappeared and the level of
ammonium decreased to 12 mmol/l.
4. Discussion
VHA is a condition characterized by elevation of plasma level of
ammonium above 40 mmol/l. It may be asymptomatic or presents
as VHE.1 Mild and transient hyperammonemia (HA) occurs
frequently during VPA therapy.23 VHE is without clinical or
laboratory evidence of hepatotoxicity and can occur at normal
therapeutic VPA blood levels. The four patients were prescribed
Table 2
A review of VHE in children.
Author Sex/age Diagnosis VHE symptoms Daily dose
of VPA (mg)
Associated
medications
Ammonia
level (mmol/l)
VPA level
(mmol/l)
Duration
of therapy
Carlson et al. (2007)7 M – 11 Aspergers syndrome
ADHD
Mania and psychosis
Agitation
Disrobing
Vomiting
750 Lithium
Ariprazole
Dextroamphetamine
213 603–624 NA
Cheung et al. (2004)8 M – 15 Mental retardation and
inverted duplication
for chromosome
15. Epilepsy
Irritability
Drowsiness, Decreased
appetite
Increased minor
seizures.
42 mg/kg Topiramate
Phenytoin
61 774 NA
Chou et al. (2008)25 F – 14 Absence seizures Dizziness
Malaise
Vomiting
Lethargy
1000 None 184 1261 3 weeks
Young et al. (2010)36 M – 15 Bipolar disorder
MODY
Sleepiness 1750 Lithium
Haloperidol
Herbal medicine
96 693 NA
Abbreviations: NA, not available; M, male; F, female; MODY, Mature onset diabetes of the young.
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within the therapeutic recommended levels. All received VPA in
poly-therapy, and in case 1 an anti-psychotic drug was adminis-
tered as well. In children, poly-therapy has been reported to be a
risk factor of VHA and VHE.2,7,8,23 Yamamoto et al.22 reported
concomitant use of phenytoin, phenobarbital and topiramate as a
risk factor of VHE in children. Adults receiving phenytoin,
phenobarbital and carbamazepine in combination with VPA also
experienced increased ammonium levels.9,10,23 Topiramate was
prescribed in combination with phenobarbital and VPA in one
patient.10 Furthermore, poly-therapy has been described as a risk
factor of VHE in the psychiatric setting,11–14 among mentally
impaired individuals,15,16 and among elderly.17 Tables 2 and 3
summarize the existing case reports of VHE in children and adults.
A systematic review concluded that measurement of ammoni-
um in asymptomatic patients treated with VPA is unnecessary,21
and that VPA should not be discontinued solely on the basis of HA.
Other studies emphasize the need for measurements of ammoni-
um level in patients with multiple risk factors such as being under
2 years of age, VPA level higher than the therapeutic range, poly-
therapy, concomitant use of other anti-epileptic drugs, and in
those with known carnitine deﬁciency or congenital abnormalities
of the urea cycle.2,9,22,24
The clinical manifestations of VHE include an acute or sub-
acute decrease in consciousness level with progression from
drowsiness to lethargy and coma. Symptoms like confusion,
personality change, irritability, ataxia, visual disturbance, lethargy,
focal neurological deﬁcits, nausea, vomiting and increased seizure
frequency occur. These ﬁndings may even lead to an increase in
VPA dose before diagnosis, with the consequent worsening.1,11,24
VHE can occur with normal dose and plasma levels of VPA,25 and
liver parameters are most often quite normal. The four cases all
showed signs of VHE. Symptoms occurred shortly after com-
mencement or increase in dose of VPA. Electro-encephalograms
(EEGs) were not performed in any of our cases. However, the
symptoms disappeared immediately after discontinuation of VPA
(cases 1 and 2) or administration of carnitine (cases 3 and 4), which
strongly argues against a non-convulsive status epilepticus as the
cause of the drowsiness and lethargy reported in the cases.
4.1. Pathophysiology of VHE
VPA can lead to VHE because of several mechanisms. An
increased uptake of glutamine and the release of ammonium in the
kidneys favors HA mediated by a VPA metabolite, sodium 2-
propyl-4-pentenoate. Furthermore, the VPA metabolitespropionate and 4-en-VPA reduces levels of hepatic N-acetylglu-
tamate (NAG) and a decrease in acetyl-CoA which inhibits the urea
cycle and diminishes the removal of ammonia. Drugs like
phenytoin, phenobarbital and carbamazapine leads to an increase
in 4-en-VPA resulting in HA, which may explain why polytherapy
favors development of HA and VHE.24
VHE occurs as a course of reduced glutamine synthesis in the
brain by VPA. Furthermore, intracellular concentrations of gluta-
mate and ammonium in astrocytes increase, and cerebral edema,
raised intracranial pressure and neuronal damage develops.26 VPA
is a short chain fatty acid which requires carnitine for oxidation.
VPA combines with carnitine within the mitochondria resulting in
valproylcarnitine ester, which then is transported out of the
mitochondria and eliminated in the urine, thus depleting carnitine
stores.27 Overall, ammonia concentrations are directly correlated
with the dosage and serum concentrations of valproic acid and
inversely correlated with serum concentrations of carnitine.28
4.2. Carnitine deﬁciency and hyperammonemia
Carnitine deﬁciency (CD) can be an isolated autosomal
recessive disorder, or can arise from secondary causes, such as
inborn errors of metabolism, renal failure, hepatic disease,
malnutrition, or the use of medications, such as VPA.29 In a
prospective study, Hamed et al.3 described that plasma ammoni-
um concentration was signiﬁcantly elevated in VPA mono-therapy
and poly-therapy after one year of treatment. Among 60 patients
treated with VPA, 38 developed low levels of carnitine and received
treatment with carnitine. In addition, a signiﬁcant decrease in total
or free blood carnitine concentrations or both has been reported in
patients receiving antiepileptic polypharmacy.30 Carnitine has
been found to be beneﬁcial in treatment of VHE following either a
VPA overdose or usual dosages of VPA.28 Supplementation with
carnitine has been recommended in children on VPA therapy, who
receive more than one anticonvulsant, have a poor nutritional
status, or are following a ketogenic diet. In adults, carnitine
treatment may be considered if there are impairment of hepatic
parameters, presence of HA, a signiﬁcant decrease in serum free
carnitine levels, or symptoms suggestive of CD.31 Administration of
exogenous carnitine reduces level of ammonium by binding to VPA
and relieving the inhibition of urea synthesis. Several studies
suggest that supplementation with carnitine reduces the ammo-
nium level.27,28,31,32 In the present case series, treatment with
carnitine was not tried in case 1 or 2, but signiﬁcantly reduced
ammonium levels were seen concomitant to carnitine adminis-
tration in cases 3 and 4, despite unchanged administration of VPA.
Table 3
A review of VHE in adults.
Author Sex/age Diagnosis VHE symptoms Daily dose
of VPA (mg)
Associated
medications
Ammonia level
(mmol/l)
VPA level
(mmol/l)
Duration
of therapy
Gomez-Iban˜ez et al. (2011)10 F – 49 Epilepsy with tonic-clonic
seizures and partial complex
seizures
Behavioral change
Involuntary movements
Disorientation
Aphasia
Unsteady gait
1500 Phenobarbital
Topiramate
115 416 5 years
Shan et al. (2010)13 M – 41 Schizophrenia Drowsiness
Sleepiness
Unsteady gait
Unconsciousness
1500 Zotepine 182 866 18 days
McCall et al. (2004)14 F – 62 Brain aneurism repair with
seizure disorder
Previously traumatic brain
injury.
Anxiety
Hypertension
Hypothyroidism
Fibromyalgia
Chronic pain
Decreased level of
consciousness
Confusion
Dizziness
Lethargy
Several falls
250 Estradiol
Levothyroxine
Diazepam
Cyclobenzaprine
Trazodone
Acetaminophen
Codeine
Sulindac
99 520 NA
Khoo et al. (2010)16 F – 38 Mental retardation, Episodes of
agitation, irritability and
aggression
Fluctuations of agitation
and sedation.
Unsteady gait.
1500 Quetiapine
Fluoxetine
Fluphenanzine
Decanoate
130 631 18 years
Wadzinski et al. (2007)37 F – 51 PTSD
Migraine Depression
Unresponsiveness 1000 Topiramate
Quetiapine
232 (10–47) 1005 7 days
Wadzinski et al. (2007)37 F – 29 OCD
Bipolar disorder
Short-term memory
Confusion Disorientation
Hypersomnia Blurred
vision Slurred speech
Ataxia
1500 Fluvoxamine
Clonazepam
182 (10–47) 783 5 months
Eubanks et al. (2008)38 F – 33 Bipolar disorder
PTSD
Borderline personality
Unresponsiveness 1500 Clonazepam
Venlafaxine
Mirtazapine
Buprionon
Hydroxyzine
283 (2–30) 832 3 days
Cuturic et al. (2005)39 F – 56 Idiopathic complex partial
epilepsy with secondary
generalization
Confusion
Drowsiness
Unresponsiveness
2500–3000 Carbamazepine, Gabapentin 479 (12–46) 568 NA
Deutsch S et al. (2009)40 F – 31 Bipolar disorder with psychotic
features, borderline
personality, and migraine
Somnolence
Irritability
Dysarthry
Ataxia
Hearing voices
1000 Citalopram
Topiramata
41 (9–35) 721 2 weeks
Velioglu et al. (2007)41 M – 19 2 seizures 1 year before Dizziness
Ataxia
Drowsiness, Nausea
Reduced level of
consciousness
500 NA 70 (9–33) 277 4 days
Feil et al. (2012)42 M – 88 Seizure disorder of unknown
etiology
Confusion 250 NA 490 (19–60) 333 2 months
Hung et al. (2011)43 F – 21 Hallucinations and aggressive
behavior
Nausea
Vomiting Drowsiness
Disorientation Ataxia
500–750 NA 133 742 4 days
Soares-Fernandes et al. (2006)44 F – 45 Epilepsy Somnolence
Coma
1600 Phenytoin
Phenobarbital
479 305 1 day
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Batten disease is caused by accumulation of lysosomal storage
bodies. A signiﬁcant constituent of this storage is the protein
subunit c of ATP synthetase, which contains a trimethyl lysine
(TML) residue. Presence of TML in the stored protein leads to
degradation of the protein, thus releasing free TML. Free TML is the
ﬁrst intermediate in the carnitine pathway. Thus, accumulation of
TML containing subunit c leads to CD.33 Katz33 examined 80 people
who either were patients with Batten disease, carriers of the
disease, or controls. Mean total and free carnitine concentration in
patients with Batten disease were 63% respectively 61% of the
levels observed in normal controls. In a dog model of JNCL, half of
the attended had improvement in symptoms when treated with
carnitine as a dietary supplement, compared to non-treated34 and
in a mouse study,35 carnitine supplementation signiﬁcantly
increased life expectancy. In addition, following 25 weeks of
carnitine treatment the mice had signiﬁcantly less storage material
in the cortical neurons than mice without carnitine treatment. The
authors suggested, that carnitine may act via a feedback
mechanism which slows the synthesis of TML containing subunit
c. So far, no study of carnitine treatment in JNCL patients has been
published, but these observations suggest, that patients with JNCL
may have an increased risk of developing HA or even VHE when
treated with VPA. In the present case series, four of 14 patients
treated with VPA in poly-therapy had VHE, but as measurements of
ammonium were not performed on routine, further patients may
have had an asymptomatic increase in ammonium that could
ultimately result in development of VHE.
5. Conclusion
Patients with JNCL are in great risk of developing VHE due to a
high rate of poly-pharmacy. In addition, carnitine levels may be
depressed in Batten disease, which might be a second reason for an
increased risk of VHE. We therefore recommend that increased
attention to VHA/VHE should be given to these patients.
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